Intellia Therapeutics to Release World's First In Vivo CRISPR Phase 3 Data on April 27
Intellia Therapeutics will report topline Phase 3 results for lonvoguran ziclumeran in hereditary angioedema on April 27, 2026 — the first Phase 3 readout for any in vivo CRISPR candidate.
4 min read5 sources